[Treatment of wet age-related macular degeneration with vascular endothelial growth factor. A survey of a Cochrane review].
This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity.
Bloch
Sara Brandi
SB
Øjenafdelingen, Glostrup Hospital, DK-2600 Glostrup, Denmark. sabrbl01@glo.regionh.dk
Larsen
Michael
M
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D011166:Porphyrins / Q000627:therapeutic use; D000069579:Ranibizumab; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*; D057135:Wet Macular Degeneration / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D011166:Porphyrins; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000069579:Ranibizumab